Not finding it? Sign in to also search OpenAlex live.
-
Longer-term safety of pimicotinib in tenosynovial giant cell tumor (TGCT): Integrated analysis of phase 1 and phase 3 MANEUVER trial data.2026 Journal of Clinical Oncology conference-abstract Medicine Musculoskeletal synovial abnormalities and treatments
Hans A. J. Gelderblom, Vinod Ravi, Vishal Ghori, Aimar Zhang, Niki Karachaliou, Boyao Shan, +2 more
0citations -
Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
Steffen Koschmieder, Susanne Isfort, Lino Lars Teichmann, Philippe Schafhausen, Florian Heinrich Heidel, Andreas Hochhaus, +18 more
4citations -
Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) - an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
Susanne Isfort, Kirsi Marjaana Manz, Lino Lars Teichmann, Martina Margrit Crysandt, Andreas Burchert, Andreas Hochhaus, +18 more
0citations -
1628MO A new benchmark for designing phase II trials for advanced or metastatic leiomyosarcoma (LMS) patients using progression free survival (PFS) as primary endpoint – an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis
Georgios Kantidakis, Saskia Litière, Anouk Neven, Marie Vinches, Ian Robert Judson, Patrick Schöffski, +7 more
0citations -
7425 Biochemical Response, Symptom Control, and Safety of Oral Octreotide Capsules Treatment in Acromegaly: A Post Hoc Analysis of a Large Pooled Database from Three Phase 3 Clinical Trials2024 Journal of the Endocrine Society article Medicine Pituitary Gland Disorders and Treatments Open access
Maria Fleseriu, Susan Leanne Samson, Nienke Ruurdje Biermasz, Christian Joseph Strasburger, Shir Fuchs Orenbach, Jason A. Crompton, +1 more
0citations -
Antithrombotic Usage, Including Three-Year Outcomes With Dabigatran and Vitamin K Antagonists for Atrial Fibrillation, in Eastern Europe: A Descriptive Analysis From Phase 3 of the GLORIA-AF Registry2023 American Journal of Therapeutics article Medicine Atrial Fibrillation Management and Outcomes Open access
Jutta K Bergler-Klein, Nina N. Gotcheva, Oskars Kalējs, Zbigniew F. Kalarus, Dragan Kovačić, Viktor Peršić, +5 more
0citations -
Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC
Pasi Antero Janne, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang‐We Kim, David Planchard, +13 more
35citations -
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial2023 Annals of Hematology article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Steffen Koschmieder, Susanne Isfort, Lutz Jacobasch, Thomas Geer, Marcel Reiser, Michael Koenigsmann, +8 more
13citations -
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial
Patrick Schöffski, Suzanne George, Michael Charles Heinrich, John Raymond Zalcberg, Sebastian Bauer, Hans A. J. Gelderblom, +12 more
10citations -
Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
Steffen Koschmieder, Susanne Isfort, Florian Heinrich Heidel, Andreas Hochhaus, Heiko Becker, Philipp Jakob Jost, +19 more
3citations -
Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
Andrew Jay Portuguese, Sherilyn Alvaran Tuazon, Margot J. Pont, Gabriel O. Cole, Blythe Duke Sather, Xiaoling Song, +17 more
0citations -
P271 To what extent are baseline characteristics in biologic-experienced patients with psoriatic arthritis associated with achievement of minimal disease activity at week 24 of guselkumab treatment: a post hoc analysis of the phase IIIb COSMOS clinical trial
William L. Tillett, Sarah Ohrndorf, Julio A. Ramírez, Marlies Neuhold, Robert Wapenaar, Elke Theander, +4 more
0citations -
Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study2020 The Nephron journals/Nephron journals article Medicine Parathyroid Disorders and Treatments Open access
Adrian Constantin Covic, Stuart Michael Sprague, Anjay Rastogi, Markus Ketteler, Sebastian Walpen, Amandine Perrin, +1 more
4citations